Knight Total Stockholder Equity vs Net Tangible Assets Analysis

GUD Stock

CAD 6.00 0.21 3.63%

Knight Therapeutics financial indicator trend analysis is infinitely more than just investigating Knight Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Knight Therapeutics is a good investment. Please check the relationship between Knight Therapeutics Total Stockholder Equity and its Net Tangible Assets accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

Total Stockholder Equity vs Net Tangible Assets

Total Stockholder Equity vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Knight Therapeutics Total Stockholder Equity account and Net Tangible Assets. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Knight Therapeutics' Total Stockholder Equity and Net Tangible Assets is 0.54. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Knight Therapeutics, assuming nothing else is changed. The correlation between historical values of Knight Therapeutics' Total Stockholder Equity and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Knight Therapeutics are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Total Stockholder Equity i.e., Knight Therapeutics' Total Stockholder Equity and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Knight Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Knight Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

At this time, Knight Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 1st of June 2024, Enterprise Value Over EBITDA is likely to grow to 10.50, though Tax Provision is likely to grow to (4.9 M).

	2021	2022	2023	2024 (projected)
Interest Expense	3.6M	6.6M	12.5M	9.4M
Depreciation And Amortization	47.9M	62.6M	72.0M	75.6M

Interest Expense Depreciation And Amortization

Knight Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Total Current Assets	Common Stock	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Non Current Assets Total	Other Assets	Net Receivables	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Long Term Investments	Property Plant And Equipment Gross
Total Assets		0.96	-0.38	0.51	0.64	0.98	0.93	0.87	0.98	0.4	0.61	0.38	0.64	0.58	0.34	0.59	0.79	0.35	0.65	0.38	0.6	0.4	0.83	0.64	0.91	0.58
Total Stockholder Equity	0.96		-0.53	0.65	0.76	0.98	0.93	0.92	0.99	0.19	0.37	0.54	0.46	0.34	0.55	0.43	0.66	0.19	0.46	0.48	0.44	0.18	0.75	0.41	0.88	0.43
Net Debt	-0.38	-0.53		-0.99	-0.92	-0.44	-0.42	-0.74	-0.5	0.05	0.25	-0.83	0.33	0.29	-0.38	0.45	0.22	-0.13	0.34	-0.62	0.45	0.06	0.08	0.31	-0.34	0.41
Cash	0.51	0.65	-0.99		0.95	0.56	0.53	0.82	0.62	0.02	-0.12	0.81	-0.19	-0.16	0.39	-0.3	-0.07	0.17	-0.19	0.6	-0.3	0.01	0.07	-0.17	0.44	-0.27
Cash And Short Term Investments	0.64	0.76	-0.92	0.95		0.67	0.67	0.91	0.73	0.12	-0.01	0.87	-0.11	-0.06	0.44	-0.22	0.06	0.25	-0.1	0.78	-0.22	0.12	0.19	-0.06	0.64	-0.2
Common Stock Total Equity	0.98	0.98	-0.44	0.56	0.67		0.91	0.87	0.99	0.24	0.47	0.43	0.55	0.46	0.46	0.53	0.75	0.21	0.58	0.38	0.55	0.24	0.84	0.53	0.87	0.54
Common Stock Shares Outstanding	0.93	0.93	-0.42	0.53	0.67	0.91		0.86	0.93	0.35	0.5	0.56	0.53	0.45	0.47	0.44	0.69	0.35	0.5	0.53	0.46	0.34	0.74	0.5	0.97	0.42
Total Current Assets	0.87	0.92	-0.74	0.82	0.91	0.87	0.86		0.91	0.29	0.31	0.72	0.21	0.25	0.4	0.17	0.38	0.31	0.24	0.67	0.18	0.29	0.48	0.28	0.83	0.12
Common Stock	0.98	0.99	-0.5	0.62	0.73	0.99	0.93	0.91		0.26	0.46	0.5	0.51	0.43	0.47	0.47	0.7	0.25	0.53	0.45	0.49	0.26	0.79	0.49	0.89	0.46
Other Current Liab	0.4	0.19	0.05	0.02	0.12	0.24	0.35	0.29	0.26		0.87	-0.06	0.5	0.84	-0.63	0.32	0.39	0.88	0.53	0.18	0.29	1.0	0.22	0.75	0.44	0.27
Total Current Liabilities	0.61	0.37	0.25	-0.12	-0.01	0.47	0.5	0.31	0.46	0.87		-0.25	0.83	0.99	-0.45	0.74	0.76	0.69	0.87	-0.06	0.72	0.87	0.61	0.98	0.54	0.69
Net Tangible Assets	0.38	0.54	-0.83	0.81	0.87	0.43	0.56	0.72	0.5	-0.06	-0.25		-0.36	-0.32	0.56	-0.43	-0.18	0.11	-0.37	0.88	-0.42	-0.07	-0.02	-0.32	0.55	-0.45
Property Plant And Equipment Net	0.64	0.46	0.33	-0.19	-0.11	0.55	0.53	0.21	0.51	0.5	0.83	-0.36		0.86	-0.1	0.85	0.93	0.43	0.94	-0.31	0.87	0.5	0.8	0.89	0.5	0.9
Current Deferred Revenue	0.58	0.34	0.29	-0.16	-0.06	0.46	0.45	0.25	0.43	0.84	0.99	-0.32	0.86		-0.46	0.74	0.78	0.68	0.89	-0.14	0.74	0.84	0.63	0.98	0.49	0.72
Retained Earnings	0.34	0.55	-0.38	0.39	0.44	0.46	0.47	0.4	0.47	-0.63	-0.45	0.56	-0.1	-0.46		-0.05	0.15	-0.49	-0.18	0.38	-0.01	-0.63	0.33	-0.36	0.41	0.01
Accounts Payable	0.59	0.43	0.45	-0.3	-0.22	0.53	0.44	0.17	0.47	0.32	0.74	-0.43	0.85	0.74	-0.05		0.89	0.07	0.92	-0.36	0.99	0.32	0.83	0.84	0.42	0.94
Non Current Assets Total	0.79	0.66	0.22	-0.07	0.06	0.75	0.69	0.38	0.7	0.39	0.76	-0.18	0.93	0.78	0.15	0.89		0.27	0.92	-0.11	0.9	0.39	0.95	0.85	0.68	0.93
Other Assets	0.35	0.19	-0.13	0.17	0.25	0.21	0.35	0.31	0.25	0.88	0.69	0.11	0.43	0.68	-0.49	0.07	0.27		0.36	0.27	0.08	0.88	0.1	0.55	0.43	0.08
Net Receivables	0.65	0.46	0.34	-0.19	-0.1	0.58	0.5	0.24	0.53	0.53	0.87	-0.37	0.94	0.89	-0.18	0.92	0.92	0.36		-0.27	0.91	0.52	0.84	0.95	0.49	0.94
Short Term Investments	0.38	0.48	-0.62	0.6	0.78	0.38	0.53	0.67	0.45	0.18	-0.06	0.88	-0.31	-0.14	0.38	-0.36	-0.11	0.27	-0.27		-0.37	0.17	-0.01	-0.15	0.62	-0.41
Inventory	0.6	0.44	0.45	-0.3	-0.22	0.55	0.46	0.18	0.49	0.29	0.72	-0.42	0.87	0.74	-0.01	0.99	0.9	0.08	0.91	-0.37		0.3	0.84	0.83	0.43	0.92
Other Current Assets	0.4	0.18	0.06	0.01	0.12	0.24	0.34	0.29	0.26	1.0	0.87	-0.07	0.5	0.84	-0.63	0.32	0.39	0.88	0.52	0.17	0.3		0.21	0.75	0.43	0.26
Other Stockholder Equity	0.83	0.75	0.08	0.07	0.19	0.84	0.74	0.48	0.79	0.22	0.61	-0.02	0.8	0.63	0.33	0.83	0.95	0.1	0.84	-0.01	0.84	0.21		0.73	0.7	0.86
Total Liab	0.64	0.41	0.31	-0.17	-0.06	0.53	0.5	0.28	0.49	0.75	0.98	-0.32	0.89	0.98	-0.36	0.84	0.85	0.55	0.95	-0.15	0.83	0.75	0.73		0.53	0.82
Long Term Investments	0.91	0.88	-0.34	0.44	0.64	0.87	0.97	0.83	0.89	0.44	0.54	0.55	0.5	0.49	0.41	0.42	0.68	0.43	0.49	0.62	0.43	0.43	0.7	0.53		0.39
Property Plant And Equipment Gross	0.58	0.43	0.41	-0.27	-0.2	0.54	0.42	0.12	0.46	0.27	0.69	-0.45	0.9	0.72	0.01	0.94	0.93	0.08	0.94	-0.41	0.92	0.26	0.86	0.82	0.39

Click cells to compare fundamentals

Knight Therapeutics Account Relationship Matchups

Knight Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.0B	991.9M	1.1B	945.5M	952.1M
Total Stockholder Equity	810.7M	886.2M	842.0M	825.9M	746.9M	823.4M
Net Debt	(107.1M)	(173.4M)	(45.0M)	6.0M	3.1M	3.3M
Cash	169.3M	229.6M	86.0M	71.7M	58.8M	55.8M
Cash And Short Term Investments	430.6M	411.3M	163.0M	191.2M	172.1M	163.5M
Common Stock Total Equity	761.5M	761.8M	723.8M	694.4M	798.5M	616.3M
Common Stock Shares Outstanding	140.1M	132.0M	124.5M	114.9M	101.2M	123.2M
Total Current Assets	698.2M	554.6M	307.3M	395.6M	365.1M	556.5M
Common Stock	723.8M	694.4M	628.9M	599.1M	688.9M	628.1M
Other Current Liab	225.6M	15.9M	11.7M	15.0M	1.0M	993.7K
Total Current Liabilities	350.8M	114.1M	105.3M	141.3M	114.0M	96.9M
Net Tangible Assets	1.0B	549.1M	652.0M	416.3M	374.7M	569.1M
Property Plant And Equipment Net	29.0M	26.2M	29.9M	22.6M	17.9M	14.0M
Current Deferred Revenue	282K	183K	39.9M	14.6M	16.8M	8.9M
Retained Earnings	52.2M	174.5M	191.6M	161.8M	150.9M	178.6M
Accounts Payable	72.8M	44.5M	65.3M	106.1M	85.4M	89.6M
Non Current Assets Total	607.1M	485.0M	684.6M	659.2M	580.4M	435.2M
Other Assets	152.0M	75.5M	57.1M	15.6M	17.9M	17.0M
Net Receivables	111.7M	82.0M	67.4M	110.2M	88.7M	52.7M
Short Term Investments	261.3M	181.7M	77.0M	119.5M	111.4M	174.0M
Liabilities And Stockholders Equity	1.3B	1.0B	991.9M	1.1B	1.2B	1.0B
Inventory	70.9M	56.5M	72.4M	92.5M	91.8M	96.4M
Other Current Assets	85.0M	4.8M	4.5M	1.7M	2.0M	1.9M
Other Stockholder Equity	17.2M	18.8M	21.9M	23.8M	27.3M	15.8M
Total Liab	390.2M	153.4M	149.9M	229.0M	198.6M	130.2M
Long Term Investments	259.7M	174.8M	179.0M	158.0M	120.0M	183.4M
Property Plant And Equipment Gross	29.0M	26.2M	41.0M	56.1M	39.5M	21.3M
Accumulated Other Comprehensive Income	17.4M	(1.5M)	(376K)	41.3M	37.1M	39.0M
Short Term Debt	52.3M	53.6M	28.3M	20.3M	18.2M	17.3M
Intangible Assets	173.4M	156.5M	350.3M	338.8M	290.0M	149.3M
Property Plant Equipment	29.0M	26.2M	29.9M	22.6M	26.0M	13.4M
Other Liab	4.6M	29.6M	36.8M	31.9M	36.7M	38.5M
Non Current Liabilities Total	39.4M	39.4M	44.6M	87.7M	84.6M	88.8M
Non Currrent Assets Other	52.7M	47.3M	47.9M	48.2M	43.4M	70.6M
Long Term Debt Total	9.8M	2.5M	12.7M	57.4M	66.1M	69.4M
Capital Surpluse	16.5M	18.7M	21.8M	23.7M	27.2M	18.3M
Cash And Equivalents	5.3M	2.6M	9.0M	302K	271.8K	258.2K
Net Invested Capital	866.3M	938.0M	877.9M	895.9M	808.7M	732.4M
Net Working Capital	270.7M	438.0M	199.7M	254.3M	251.1M	331.3M
Capital Stock	723.8M	694.4M	628.9M	599.1M	540.0M	526.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Knight Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

Note that the Knight Therapeutics information on this page should be used as a complementary analysis to other Knight Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Knight Stock analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges

Please note, there is a significant difference between Knight Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Knight Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Knight Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Knight Total Stockholder Equity vs Net Tangible Assets Analysis

Total Stockholder Equity vs Net Tangible Assets

Total Stockholder Equity vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Net Tangible Assets

Knight Therapeutics fundamental ratios Correlations

Knight Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Knight Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Knight Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Other Current Liab
Common Stock	+ 0.99	Total Stockholder Equity
Common Stock	+ 0.99	Common Stock Total Equity
Current Deferred Revenue	+ 0.99	Total Current Liabilities
Inventory	+ 0.99	Accounts Payable
Common Stock Total Equity	+ 0.98	Total Assets

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.92	Net Debt
Net Tangible Assets	- 0.83	Net Debt
Total Current Assets	- 0.74	Net Debt
Other Current Assets	- 0.63	Retained Earnings
Retained Earnings	- 0.63	Other Current Liab